Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

Thamir M Alshammari1–3
Sondus I Ata4
Mansour Adam Mahmoud5
Tariq M Alhawassji2,4,6
Hisham S Aljadhey1

1Department of Clinical Pharmacy, College of Pharmacy, University of Hai, Hail, Saudi Arabia; 2Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia; 3Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 4Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia; 5Department of Clinical Pharmacy, College of Pharmacy, Taibah University, Medina, Saudi Arabia; 6Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Purpose: To analyze and compare the signals of bleeding from the use of direct-acting oral anticoagulants (DOACs) in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database over 5 years.

Methods: Reports of bleeding and of events with related terms submitted to the FAERS between October 2010 and September 2015 were retrieved and then analyzed using the reporting odds ratio (ROR). The signals of bleeding associated with DOAC use were compared with the signals of bleeding associated with warfarin use utilizing the FAERS databases.

Results: A total of 1,518 reports linked dabigatran to bleeding, accounting for 2.7% of all dabigatran-related reports, whereas 93 reports linked rivaroxaban to bleeding, which accounted for 4.4% of all rivaroxaban-related reports. The concurrent proportion of bleeding-related reports for warfarin was 3.6%, with a total of 654 reports. The association of bleeding and of related terms with the use of all three medications was significant, albeit with different degrees of association. The ROR was 12.30 (95% confidence interval [CI] 11.65–12.97) for dabigatran, 15.61 (95% CI 14.42–16.90) for warfarin, and 18.86 (95% CI 15.31–23.23) for rivaroxaban.

Conclusions: The signals of bleeding varied among the DOACs, and the bleeding signal was higher for rivaroxaban and lower for dabigatran compared to that for warfarin.

Keywords: Warfarin, dabigatran, rivaroxaban, FAERS, bleeding

Introduction

Oral anticoagulants are widely prescribed for patients with venous thromboembolism. Specific scoring systems are useful for determining who should use oral anticoagulants for diseases such as atrial fibrillation. The CHADS2 scoring system is widely used to stratify the risk of thromboembolism in atrial fibrillation patients. Patients at low risk (CHADS2 score = 0) should not be treated with oral anticoagulants, whereas patients at higher risk (CHADS2 score ≥ 2) should be treated. An updated version of CHADS2 is the CHA2DS2-VASc score, which is used by the European Society of Cardiology and the American College of Cardiology. Evidence indicates that patients with atrial fibrillation at moderate to high thromboembolic risk (CHA2DS2-VASc ≥ 2) should be treated with oral anticoagulants. Additionally, patients with CHA2DS2-VASc scores of 1 for men or 2 or above for women should be considered for anticoagulant therapy to prevent stroke.1–4 Warfarin was considered the gold standard anticoagulant...
therapy to prevent stroke and to prevent and treat deep venous thrombosis and pulmonary embolism for many years, albeit the only option available at the time. Warfarin was also used to prevent and treat thromboembolic complications in patients with cardiac valve replacement and/or atrial fibrillation and to reduce the risk of death, stroke or systemic embolization after myocardial infarction and recurrent myocardial infarction. It is also used for patients with cerebral transient ischemic attack. However, warfarin is a narrow therapeutic index drug, which encumbers the maintenance of patients at the required therapeutic level. A study found that approximately 50% of patients were out of the normal therapeutic range. Moreover, inter-individual variability in response to warfarin therapy exists, which causes warfarin dose variance among patients. Therefore, patients using warfarin require close monitoring, particularly at the beginning of treatment, because of the risk of bleeding and potential drug interactions.

Direct-acting oral anticoagulants (DOACs) were introduced to the market in the new century. Two classes of DOACs are currently available: oral direct thrombin inhibitors (DTIs; eg, dabigatran) and oral direct factor Xa inhibitors (eg, rivaroxaban, apixaban, edoxaban, and betrixaban). Dabigatran was approved by the US Food and Drug Administration (FDA) in October 2010 for the prevention of stroke in patients with non-valvular atrial fibrillation. Rivaroxaban and dabigatran are prescribed as alternatives to warfarin to prevent stroke in patients with atrial fibrillation. Furthermore, as per the CHEST (2016) guidelines, rivaroxaban and dabigatran may be used preferentially over warfarin as an anticoagulant therapy for venous thromboembolism.

Clinical trials demonstrated that dabigatran was comparable to warfarin regarding efficacy and safety. Some of the advantages of dabigatran over warfarin include the lack of a need for routine blood monitoring, a standard dosing regimen and fewer drug interactions. Additionally, because of its short half-life (12-17 hours), dabigatran use may not require bridging therapy before surgery. The protein binding of dabigatran is approximately 35% and its volume of distribution is 50-70 L.

Rivaroxaban was approved by the US FDA in mid-2011 as prophylaxis for deep venous thrombosis and, later in the same year, for the prevention of stroke in patients with non-valvular atrial fibrillation. Rivaroxaban has high plasma protein binding (92%-95%), a volume of distribution of 50 L and a half-life of 5-9 hours. For patients with atrial fibrillation, rivaroxaban was non-inferior to warfarin for the prevention of stroke and systemic embolism. However, fatal bleeding occurred less frequently in the rivaroxaban group. Notably, the normal rivaroxaban dosage for atrial fibrillation is 20 mg once daily and, for patients with a creatinine clearance 15-50 mL/min, 15 mg once daily.

A systematic review reported no differences in the risks of non-hemorrhagic stroke and systemic embolic events between DOACs (rivaroxaban, dabigatran and apixaban) and warfarin. However, the risk of intracranial bleeding with DOAC use was lower than that with warfarin use (relative risk [RR] = 0.46; 95% CI = 0.33-0.65). Table 1 shows the landmark clinical trials for the DOACs included in the study.

Adverse drug reactions (ADRs) cannot be easily detected in studies conducted before a new drug reaches the market for use in patients. However, after the drug is marketed, new spontaneous reports of ADRs are received by health authorities as a greater number of patients are prescribed the drug for longer periods of use. Observations from real-world data indicated increased cases of major bleeding in older patients, extremely obese patients and patients with impaired renal function who were using dabigatran. Real-world data provide confirmative information on bleeding risks to help clinicians weigh the risks and benefits of these agents.

The FDA established the FDA Adverse Event Reporting System (FAERS) database to support post-marketing surveillance programs. The FAERS is a computerized database of more than nine million adverse event reports, including all reports from 1969 to the present time. Epidemiologists and other scientific personnel may access the reports submitted to the FAERS, and the FDA may depend on these reports to take action regarding medication safety concerns.

Therefore, the aim of this study was to evaluate the associations between the use of warfarin (Coumadin; Bristol-Myers Squibb, New York, NY, USA), dabigatran (Pradaxa; Boehringer Ingelheim, Ingelheim am Rhein, Germany) and rivaroxaban (Xarelto; Janssen Pharmaceutica NV, Beerse, Belgium) and the signals of bleeding using a case/non-case method. Other DOACs (apixaban and edoxaban) were not included in this study because they were approved during the study period.

**Methods**

**Data source**

Reports of bleeding events submitted to the FAERS database over 5 years (2010-2015) were retrieved and then analyzed using the reporting odds ratio (ROR). The FAERS contains adverse event and medication error reports submitted by healthcare professionals and consumers. The FAERS datasets

---

**Table 1**

<table>
<thead>
<tr>
<th>DOAC</th>
<th>Clinical Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rivaroxaban</td>
<td><strong>CHEST (2016)</strong></td>
</tr>
<tr>
<td>Dabigatran</td>
<td><strong>CHEST (2016)</strong></td>
</tr>
<tr>
<td>Warfarin</td>
<td><strong>CHEST (2016)</strong></td>
</tr>
</tbody>
</table>

**References**


**Table I** Safety and efficacy endpoints for landmark clinical trials for studied drugs

<table>
<thead>
<tr>
<th>Trials</th>
<th>Study drug(s)</th>
<th>Primary outcome</th>
<th>Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>RE-LY1,2</td>
<td>Dabigatran 110 mg</td>
<td>Stroke or systemic embolism (rate per year); dabigatran (D110 [1.53%, N = 182];</td>
<td>Major bleeding (rate per year); warfarin (3.36%, N = 404), dabigatran (D110 [2.71%, N = 326], D150 [3.11%, N = 378])</td>
</tr>
<tr>
<td></td>
<td>(N = 6,015); dabigatran 150 mg (N = 6,076) vs warfarin (N = 6,022)</td>
<td>D150 [1.11%, N = 134]), warfarin (1.69%, N = 199)</td>
<td>Intracranial bleeding (rate per year); warfarin (0.74%, N = 89), dabigatran (D110 [0.23%, N = 28], D150 [0.30%, N = 36])</td>
</tr>
<tr>
<td>ROCKET-AF1,2</td>
<td>Rivaroxiban (N = 7,131) vs warfarin (N = 7,133)</td>
<td>Stroke or systemic embolism (intention-to-treat population) (rate per year); rivaroxiban (1.7%, N = 188), warfarin (2.2%, N = 240)</td>
<td>Major and non-major (rate per year); rivaroxiban (14.9%, N = 1,475), warfarin (14.5%, N = 1,449)</td>
</tr>
<tr>
<td>RE-MEDY2</td>
<td>Dabigatran 150 mg</td>
<td>Recurrent VTE; dabigatran (N = 26, 1.8%), warfarin (N = 18, 1.3%)</td>
<td>Major bleeding; dabigatran (N = 13, 0.9%), warfarin (N = 25, 1.8%)</td>
</tr>
<tr>
<td></td>
<td>(N = 1,430) vs warfarin (N = 1,426)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RECORD I3</td>
<td>Rivaroxiban vs enoxaparin</td>
<td>DVT, pulmonary embolism; rivaroxiban (18 of 1,595, 1.1%), enoxaparin (58 of 1,558, 3.7%)</td>
<td>Major bleeding; rivaroxiban (6 of 2,209, 0.3%), enoxaparin (2 of 2,224, 0.1%)</td>
</tr>
<tr>
<td>RE-NOVATE (I, II)**</td>
<td>Dabigatran vs enoxaparin</td>
<td>VTE; dabigatran (114 of 1,672, 6.8%), enoxaparin (129 of 1,682, 7.7%)</td>
<td>Major bleeding; dabigatran (37 of 2,156, 1.7%), enoxaparin (27 of 2,157, 1.3%)</td>
</tr>
<tr>
<td>RE-COVER3</td>
<td>Dabigatran (N = 1,274) vs warfarin (N = 1,265)</td>
<td>VTE; dabigatran (N = 30, 2.4%), warfarin (N = 27, 2.1%)</td>
<td>Major bleeding; dabigatran (N = 20, 1.6%), warfarin (N = 24, 1.9%)</td>
</tr>
<tr>
<td>RE-MODEL4</td>
<td>Dabigatran (150 mg, 220 mg) vs enoxaparin 40 mg</td>
<td>VTE; dabigatran (D150 [213 of 526, 40.5%], D220 [183 of 503, 36.4%]), enoxaparin (193 of 512, 37.7%)</td>
<td>Major bleeding; dabigatran (D150 [1.3%], D220 [1.5%]), enoxaparin (1.3%)</td>
</tr>
<tr>
<td></td>
<td>(N = 1,475), warfarin (N = 1,449)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RE-MOBILIZE4</td>
<td>Dabigatran (150 mg, 220 mg) vs enoxaparin 30 mg</td>
<td>VTE (%); dabigatran (D150 [33.7%], D220 [31.1%]), enoxaparin (25.3%)</td>
<td>Major bleeding; dabigatran (D150 [0.6%], D220 [0.6%]), enoxaparin (1.4%)</td>
</tr>
</tbody>
</table>

**Abbreviations:** DVT, deep vein thrombosis; VTE, venous thromboembolism.

may be freely accessed using the FDA website ([https://open.fda.gov/data/faers](https://open.fda.gov/data/faers)). The FAERS accepts reports from all regions of the country and from international manufacturers. Adverse event reporting by pharmaceutical companies is mandatory, whereas reporting by healthcare professionals is voluntary. Inclusion in the database, reports must include an identifiable patient, an identifiable reporter, the suspected drug and the adverse event encountered.

### Data collection

The FDA publishes FAERS files every quarter (ie, four comprehensive files published each year). Each quarterly file consists of seven sub-files, which include the following: a demographic file that includes patient demographic and administrative data; a drug file that includes drugs that the patient has taken, including suspected and any concomitant drugs; a reaction file that includes the medical dictionary for regulatory activities terms coded for the adverse event (the FDA, similar to other authorities, uses these preferred terms as the main terms for adverse events); an outcome file that includes patient outcomes for the event; a source file that contains the sources of reports; a file of therapy dates that includes drug therapy start dates and end dates for the reported drugs; and a file with indications for use that includes the medical dictionary for regulatory activities coding for indications for use (diagnoses) for the reported drugs. All these files include one unique report ID, which is referred to as the primary ID in files from 2013 and as the individual safety report (ISR) before 2013. These unique IDs were used to merge all these files both within and between years.

Reports of each bleeding event in the present analysis were submitted to the FAERS between October 2010 and September 2015, and the medications of interest that were considered a potential cause of bleeding were retrieved. The main medications of interest were warfarin, dabigatran and rivaroxaban. Searches were performed using both the generic and brand names of each medication. Additionally, searches were performed for subsets of medication-related terms (as a part of the word), and findings were reviewed case by case. Drug indications were also assessed to ensure that no discrepancies existed between the drug and its indication. Moreover, we included only the drug suspected to be the primary agent.

The outcome of interest was bleeding and was searched for using the terms “bleed,” “bleeding,” “hemorrhage” and “haemorrhage” in the preferred terms field in the FAERS database. Other data on demographic information and reporter type were also collected. Duplicate reports and contradictory
data were excluded by reviewing the unique ID (primary ID or ISR) and the case number (CASE or CASEID).

**Statistical analysis**
The case/non-case methodology was used to evaluate the association between bleeding and the use of the drugs of interest. Cases were defined as reports of the outcome of interest, ie, bleeding, and were identified by searching for related terms such as “bleed,” “bleeding,” “hemorrhage” and “haemorrhage” or subsets of these terms in the preferred terms field. Cases were extracted based on the preferred terms for any given drug. The temporal relationship between the start and event dates (ie, start dates preceding event dates) was assessed because it is an important factor in case identification. A case by case review was conducted by the research team to ascertain the time points described above.

Non-cases were defined as all non-bleeding-related reports for the same drug. Reports indicating a drug of interest as the primary suspected drug were included in the analyses. The ROR was used to evaluate the association between the drugs of interest and bleeding. The ROR estimates the odds of bleeding among those exposed to the drugs of interest divided by the odds of bleeding among those not exposed to the drugs of interest. The case/non-case report ratio for each group was compared to that of the other medications. As mentioned above, this method is used in most of the studies using spontaneous ADR reporting databases to calculate ROR, which is obtained by the equation (ad*bc), where a is the number of cases for the studied drug, b is the number of non-cases for the studied drug, c is the number of cases for other drugs in the database, and d is the number of non-cases for other drugs in the database.29 All statistical analyses were conducted using Statistical Analysis Software (SAS 9.3) (SAS Institute Inc., Cary, NC, USA).

**Confidentiality**
The study investigators had no access to the personal patient and reporter data during the review and analysis of reports from the FAERS database. This study was approved by the medication safety research chair at King Saud University.

**Table 2** Demographic distribution of reports

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Dabigatran</th>
<th>Rivaroxaban</th>
<th>Warfarin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>51.63%</td>
<td>78.05%</td>
<td>70.47%</td>
</tr>
<tr>
<td>Female</td>
<td>48.37%</td>
<td>21.95%</td>
<td>29.53%</td>
</tr>
<tr>
<td>FDA year</td>
<td>2014</td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Reporting country</td>
<td>US, France and Canada</td>
<td>US, UK and Japan</td>
<td>US, UK and Italy</td>
</tr>
<tr>
<td>Source of the report</td>
<td>Consumers</td>
<td>Pharmacists</td>
<td>Consumers</td>
</tr>
</tbody>
</table>

**Notes:** 1Year with the highest number of reports; 2Countries with the highest number of reports, listed in descending order; 3Most frequent reporting party. **Abbreviation:** FDA, the US Food and Drug Administration.

**Results**
In total, 18,231 reports were on warfarin, 56,039 reports were on dabigatran, and 2,095 reports were on rivaroxaban as the primary suspected product in the period between October 2010 and September 2015. A total of 1,518 reports linked dabigatran to bleeding, accounting for 2.7% of all dabigatran-related reports, whereas 93 reports linked rivaroxaban to bleeding, which accounted for 4.4% of all rivaroxaban-related reports. Concurrently, 654 reports linked bleeding to warfarin, which accounted for 3.6% of all warfarin-related reports. For all the drugs, most of the reports were from the US and involved male patients. However, reports of dabigatran-associated bleeding occurred at similar rates in males and females (Table 2).

The ROR was significant for the risk of bleeding with the use of all three medications, albeit with varying degrees of association. The ROR was lowest for dabigatran (12.30 [95% CI 11.65–12.97]) among the investigated medications, whereas the ROR was highest for rivaroxaban (18.86 [95% CI 15.31–23.23]) (Table 3).

The highest number of reported cases for dabigatran was for the period between 2013 and 2014, whereas for warfarin and rivaroxaban, the highest number of reported cases was for the period between 2014 and 2015 (Figure 1). Most of the bleeding reports associated with dabigatran and warfarin were sent by consumers, whereas pharmacists were the most frequent reporting party for rivaroxaban-related bleeding cases (Figure 2).

**Discussion**
Post-marketing surveillance is conducted after a new drug application is approved by the FDA to monitor the safety of medications and to identify medication-associated risks. The potential consumers after the release of a drug to market differ from the homogenous study population of the clinical trial, and thus, more valuable information may be provided from consumers than from data collected in the randomized trial.30

In this study, we demonstrated that, compared to warfarin and dabigatran, rivaroxaban was associated with a higher
The risk of bleeding. The risk of bleeding among these oral anticoagulant medications was lowest for dabigatran. Several studies reported the association between oral anticoagulants and bleeding and support our finding regarding the high risk associated with rivaroxaban use. A recent systematic review included 17 different studies and reported that rivaroxaban had a significantly higher risk of major bleeding than dabigatran (hazard ratio, 1.38; 95% CI, 1.27–1.49). Another meta-analysis of randomized controlled trials found that DOACs were associated with an increased risk of gastrointestinal bleeding, with ORs of 1.58 (95% CI, 1.29–1.93) for dabigatran and 1.48 (95% CI, 1.21–1.82) for rivaroxaban.

A study conducted in 2016 that included older adult patients (>65 years) with non-valvular atrial fibrillation reported higher rates of intracerebral hemorrhage and gastrointestinal bleeding among patients taking 20 mg of rivaroxaban daily compared with the rates among patients taking 150 mg of dabigatran twice daily.

In contrast to our study, spontaneous reports to the Australian Therapeutic Goods Administration between June 2009 and May 2014 revealed more reports of hemorrhages associated with dabigatran than those associated with rivaroxaban (504 vs 240). Compared to this Australian study, our study revealed three times more reports of bleeding due to dabigatran (504 vs 1,518) and less than half the number of reports of bleeding due to rivaroxaban (93 vs 240). The randomized evaluation of long-term anticoagulation therapy reported that the frequency of major gastrointestinal bleeding was significantly higher with dabigatran use than that with warfarin use. A limitation of the spontaneous reports submitted to the FAERS is that the reports generally do not contain data regarding the patients’ risk factors, age and renal function or whether the dose complied with the drug manufacturer’s directions. Additionally, the availability of more than one anticoagulant agent poses a challenge for healthcare professionals in choosing the appropriate option because information on which patient group is most likely to benefit from a specific drug is not yet available. One study found that patients younger than 65 years had less risk of gastrointestinal bleeding when using DOACs. This causes a dilemma because according to an epidemiological study conducted in 2010, 9% of the US population aged 80 years or older has atrial fibrillation. Moreover, older adults are less likely to be initiated on dabigatran because the risk of bleeding among adults older than 80 years is high, including at low doses such as 110 mg twice daily.

All the above-mentioned factors may affect the validity of the submitted reports, which may influence the safety alerts generated by the FDA and the regulatory authorities. Our study found that consumers were most often the reporting party. Spontaneous reporting by consumers is increasing yearly given the importance of involving patients in the reporting process. The US, along with the European Union, has facilitated consumer reporting by establishing the Adverse Medicine Events Line, electronic reporting systems and smartphone applications, such as MedWatcher.

This study has several strengths, such as the use of a rich, open-access database that includes millions of reports from the US and other countries. Furthermore, these data are not limited to US FDA researchers and may be utilized by any other researchers. However, this study also has several

### Table 3 The ROR and associated 95% CIs for bleeding following dabigatran, rivaroxaban or warfarin use

<table>
<thead>
<tr>
<th>Drug</th>
<th>Bleeding events</th>
<th>All ADRs</th>
<th>ROR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dabigatran</td>
<td>1,518</td>
<td>56,039</td>
<td>12.30</td>
<td>11.65–12.97</td>
</tr>
<tr>
<td>Warfarin</td>
<td>654</td>
<td>18,231</td>
<td>15.61</td>
<td>14.42–16.90</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>93</td>
<td>2,095</td>
<td>18.86</td>
<td>15.31–23.23</td>
</tr>
</tbody>
</table>

Abbreviations: ADR, adverse drug reactions; ROR, reporting odds ratio.
limitations, including (1) under-reporting, (2) over-reporting, (3) missing data and lack of complete information in the report, and (4) the unknown denominator for exposure.41 Additionally, we were unable to assess other DOACs (apixaban and edoxaban) because they were approved during the study period. Despite the limitations of the case/non-case method and the FAERS database, we believe that the data in this study may offer an important reference for defining the safety profile of these medications.

Conclusion
Analysis of the FAERS database suggests that the signals of bleeding vary among DOACs, ie, the bleeding signal was higher for rivaroxaban and lower for dabigatran relative to the bleeding signal for warfarin. However, all these medications have a high risk of bleeding. Healthcare professionals might consider the findings of this study along with those of previous studies in their daily medical practice.

Acknowledgments
The abstract of this study was presented as a poster abstract at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 25–28, 2016. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Disclosure
The authors report no conflicts of interest in this work.

References


